{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,11]],"date-time":"2024-09-11T20:48:23Z","timestamp":1726087703795},"reference-count":7,"publisher":"Wiley","issue":"S358","license":[{"start":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T00:00:00Z","timestamp":1187827200000},"content-version":"vor","delay-in-days":6353,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acta Psychiatr Scand"],"published-print":{"date-parts":[[1990,4]]},"abstract":"<jats:p><jats:bold>Abstract<\/jats:bold> Results for laboratory and cardiovascular variables in both short\u2010term (4\u20136 weeks) and long\u2010term (&gt;6 weeks) double\u2010blind studies in schizophrenic patients consistently showed comparably low incidences of both transient treatment\u2010emergent changes and changes present at last rating for both remoxipride and haloperidol. The total incidence of serious adverse events in the short\u2010term double\u2010blind programme was approximately 2% for both remoxipride and haloperidol. The corresponding figure for remoxipride (n=434) in long\u2010term treatment was approximately 6%. Compared to those on haloperidol, fewer patients on remoxipride had trough plasma prolactin levels above the normal range in short\u2010term treatment. The results with long\u2010term treatment with remoxipride were similar. Breast swelling and galactorrhoea were infrequent treatment\u2010emergent side effects with either drug. It was impossible to evaluate menstrual disturbance in short\u2010term studies but in long\u2010term use the incidence of treatment\u2010emergent menstrual disorder was low in remoxipride patients. Too few patients continued treatment with haloperidol for a comparative long\u2010term evaluation. Overall, based on the information available at present, remoxipride appears to offer a high degree of safety in both short\u2010term and long\u2010term treatment of schizophrenia.<\/jats:p>","DOI":"10.1111\/j.1600-0447.1990.tb05311.x","type":"journal-article","created":{"date-parts":[[2007,8,23]],"date-time":"2007-08-23T12:10:52Z","timestamp":1187871052000},"page":"164-169","source":"Crossref","is-referenced-by-count":12,"title":["Safety evaluation in both short\u2010 and long\u2010term treatment of schizophrenia with remoxipride"],"prefix":"10.1111","volume":"82","author":[{"given":"D.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Englund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Lewander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Schlachet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.\u2010E.","family":"Westerbergh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,8,23]]},"reference":[{"key":"e_1_2_1_2_2","volume-title":"Diagnostic and statistical manual of mental disorders","author":"AMERICAN PSYCHIATRIC ASSOCIATION.","year":"1980"},{"issue":"358","key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1111\/j.1600-0447.1990.tb05297.x","article-title":"Clinical profile of remoxipride \u2010 a combined analysis of a comparative double\u2010blind multicentre trial programme","volume":"82","author":"T LEWANDER.","year":"1990","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_4_2","first-page":"37931","volume":"52","author":"US DEPARTMENT OF HEALTH AND HUMAN SERVICES. FOOD AND DRUG ADMINISTRATION.","year":"1987","journal-title":"Federal Register"},{"issue":"358","key":"e_1_2_1_5_2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/j.1600-0447.1990.tb05293.x","article-title":"A controlled dose\u2010ranging study of remoxipride and haloperidol in schizophrenia \u2010aCanadian multicentre trial","volume":"82","author":"Y LAPIERRE.","year":"1990","journal-title":"Acta Psychiatr Scand"},{"key":"e_1_2_1_6_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1986.tb06225.x"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0010-440X(85)90053-7"},{"key":"e_1_2_1_8_2","volume-title":"General Register for Scotland. Mortality from cardiovascular disease tables","author":"OFFICE OF POPULATION CENSUSES AND SURVEYS.","year":"1986"}],"container-title":["Acta Psychiatrica Scandinavica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0447.1990.tb05311.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0447.1990.tb05311.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T17:55:03Z","timestamp":1697997303000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0447.1990.tb05311.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1990,4]]},"references-count":7,"journal-issue":{"issue":"S358","published-print":{"date-parts":[[1990,4]]}},"alternative-id":["10.1111\/j.1600-0447.1990.tb05311.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0447.1990.tb05311.x","archive":["Portico"],"relation":{},"ISSN":["0001-690X","1600-0447"],"issn-type":[{"value":"0001-690X","type":"print"},{"value":"1600-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[1990,4]]}}}